Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 17/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 16/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7914668 | 0.90 | MTOR (0.45) | MTORPIK3CAROCK1 | |
| SCHEMBL7911581 | 0.88 | MTOR (0.38) | MTORPIK3CAROCK1MEN1GAA | |
| SCHEMBL14790923 | 0.82 | KDM4E (0.43) | MTORROCK1ALDH1A1GAA | |
| SCHEMBL2599579 | 0.82 | MTOR (0.69) | MTORPIK3CA | |
| SCHEMBL14790900 | 0.79 | MTOR (0.54) | MTORPIK3CAALDH1A1 | |
| SCHEMBL14776693 | 0.78 | MTOR (0.55) | MTORPIK3CAPIK3CD | |
| SCHEMBL14776535 | 0.78 | MTOR (0.55) | MTORPIK3CAPIK3CD | |
| SCHEMBL14790943 | 0.77 | MTOR (0.62) | MTORPIK3CAPIK3CD | |
| SCHEMBL16310133 | 0.77 | KDM4E (0.34) | ALDH1A1 | |
| SCHEMBL14790931 | 0.75 | MTOR (0.61) | MTORPIK3CAPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912178-B2 | mTOR selective kinase inhibitors | Xcovery Holdings Company, LLC (US) | 2014-12-16 | — | — | US | disclosed |
| US-8912178-B2 | mTOR selective kinase inhibitors | Xcovery Holdings Company, LLC (US) | 2014-12-16 | — | — | US | disclosed |
| US-20130072481-A1 | mTOR SELECTIVE KINASE INHIBITORS | XCOVERY HOLDING COMPANY, LLC (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072481-A1 | mTOR SELECTIVE KINASE INHIBITORS | XCOVERY HOLDING COMPANY, LLC (US) | 2013-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072481-A1 | mTOR SELECTIVE KINASE INHIBITORS | MTOR, ULK1, ULK2 | MTOR 1/4885PIK3CA 69/4885ROCK1 1917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.